FONT-SIZE Plus   Neg

David Brennan Appointed As Non-executive Director Of Reed Elsevier - Quick Facts

Reed Elsevier Plc (ENL, REL.L) Thursday announced that Mr David Brennan has been appointed as a non-executive director of the company.

The company stated that David Brennan will assume office with effect from 1 November 2012, subject to shareholder approval at the respective Annual General Meetings to be held on 24 and 25 April 2012.

Mr Brennan is currently the Chief Executive Officer of AstraZeneca PLC, a global biopharmaceutical company, which develops, manufactures and markets prescription medicines.

Commenting on his appointment, Anthony Habgood, Chairman, said, "I would like to welcome David to Reed Elsevier. He has over 35 years experience in the biopharmaceutical industry and of the development, manufacture and commercialisation of innovative medicines. As a truly international executive with deep knowledge of the world's healthcare markets he will bring highly relevant experience to our board discussions….. '.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Large U.S. companies are holding trillions of dollars overseas in an effort to avoid U.S. taxes, with big-name firms like Apple (AAPL), Pfizer (PFE) and PepsiCo (PEP) named as notable examples. This is the claim made by a pair of non-profit groups, who released a study based on the firms' financial statements. Software maker Adobe Systems Inc. (ADBE) Tuesday detailed an outlook for the full year 2016 indicated to miss Wall Street estimates, sending its shares down 8 percent in after-hours trading. Adobe expects full-year 2016 revenues of about $5.7 billion and an adjusted earnings of $2.70 per share. Analysts... Enterprise software maker Adobe (ADBE) provided updated guidance on Tuesday, predicting strong growth over the next three years by giving 2016 projections that are below what market analysts are currently expecting.
comments powered by Disqus
Follow RTT